How to Get Trulicity in Montana: Prescriptions, Telehealth, and Pharmacy Access

What Is Trulicity and Why Montana Patients Are Seeking It

Trulicity is a branded glucagon-like peptide-1 (GLP-1) receptor agonist indicated for glycemic control in adults with type 2 diabetes and for reducing major adverse cardiovascular events (MACE) in adults with established cardiovascular disease or multiple risk factors. The FDA approved dulaglutide in September 2014, and the label was expanded in 2020 following the REWIND cardiovascular outcomes trial [1][2].

Dulaglutide works by mimicking endogenous GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Because it is dosed once weekly via a pre-filled auto-injector pen, adherence rates tend to be higher than with daily injectables [3].

Montana has seen growing demand for GLP-1 therapies as obesity and type 2 diabetes rates have risen across the state. The Montana Department of Public Health and Human Services reported that roughly 10.5% of Montana adults carried a type 2 diabetes diagnosis as of the most recent state health assessment, mirroring national CDC data showing 11.6% prevalence among U.S. adults [4]. Rural geography, limited endocrinology coverage, and telehealth expansion have all shaped how Montanans access medications like Trulicity.

How to Get a Trulicity Prescription in Montana

Getting a Trulicity prescription in Montana requires a licensed prescriber, a confirmed type 2 diabetes diagnosis (or documented cardiovascular risk under the MACE indication), and in most cases a recent set of metabolic labs. Montana allows nurse practitioners (NPs) and physician assistants (PAs) full prescriptive authority under state law, so patients are not limited to physicians alone [5].

The general pathway looks like this: schedule a visit (telehealth or in-person), share your labs and medical history, receive the prescription electronically, then route it to a pharmacy that stocks or ships dulaglutide to Montana addresses.

Step 1: Choose a prescriber type. Any MD, DO, NP, or PA licensed in Montana may prescribe Trulicity. NPs in Montana practice under full practice authority per Montana Code Annotated 37-8-405, meaning no physician supervision is required [5].

Step 2: Book an appointment. In-person visits through primary care or endocrinology clinics in Billings, Missoula, Great Falls, Bozeman, and Kalispell remain common. Telehealth platforms licensed in Montana can see patients across all 56 counties, including rural areas where the nearest endocrinologist may be 150 miles away.

Step 3: Complete the clinical evaluation. The prescriber will review your HbA1c, fasting glucose, kidney function (eGFR and serum creatinine), a lipid panel, and personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), both of which are contraindications per the FDA label [2].

Step 4: Submit the prescription. Prescriptions are sent electronically (e-prescribe) to the pharmacy of your choice. Montana pharmacies and licensed out-of-state mail-order pharmacies that are registered with the Montana Board of Pharmacy can fill branded Trulicity.

Telehealth Options for Trulicity in Montana

Montana telehealth prescribing for controlled and non-controlled medications was formally codified after 2020 federal and state regulatory updates. Dulaglutide is not a controlled substance, so a telehealth prescriber may initiate it after a synchronous audio-video visit without a prior in-person examination, provided the standard of care is met [6].

When evaluating a telehealth platform for Trulicity, look for these features:

• Montana-licensed providers (MD, DO, NP, or PA) on staff
• Ability to order or accept outside lab results
• Electronic prior authorization support for commercial insurance
• Coordination with mail-order or specialty pharmacies that ship to Montana ZIP codes

A 2023 analysis in the Journal of Telemedicine and Telecare found that GLP-1 prescriptions initiated via telehealth had 90-day refill rates comparable to those initiated in-person, suggesting telehealth does not compromise medication continuity [7]. Montana's telehealth parity law (Mont. Code Ann. 33-22-138) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services, which reduces the cost differential for patients using insurance [8].

HealthRX Montana Telehealth Readiness Checklist

Before your telehealth consult for Trulicity, gather the following so the visit is efficient and the prescription can be issued the same day:

1. HbA1c result dated within the past 90 days (or blood glucose log if no recent lab)
2. Comprehensive metabolic panel (CMP) with eGFR
3. Current medication list, including any other diabetes drugs (metformin, SGLT-2 inhibitors, sulfonylureas)
4. Personal and family history of thyroid cancer or MEN 2 documented in writing
5. Insurance card and pharmacy benefit information
6. Preferred pharmacy name and address (or willingness to use mail-order)

Labs Required Before Starting Trulicity in Montana

Most prescribers require a baseline HbA1c, a CMP, and a lipid panel before issuing the first Trulicity prescription. These labs confirm the diagnosis, establish baseline kidney function (dose adjustment is not required for eGFR above 15 mL/min/1.73 m², but monitoring is warranted), and rule out contraindications [2].

The American Diabetes Association's 2024 Standards of Care in Diabetes recommend that HbA1c be checked at least twice yearly in patients with stable glycemia, and quarterly when therapy is being initiated or changed [9]. Because Trulicity is typically initiated when HbA1c exceeds 7.0%, a documented pre-treatment value is both medically necessary and required by most insurance plans for prior authorization.

Specific labs your Montana provider will likely order or request:

• HbA1c: target baseline above 7.0% for insurance coverage; the ADA defines adequate control as below 7.0% [9]
• eGFR and serum creatinine: dulaglutide is used with caution when eGFR falls below 15 mL/min/1.73 m², per the FDA label [2]
• Fasting lipid panel: part of comprehensive diabetes management per ADA and ACC/AHA joint guidance [10]
• TSH: not universally required, but helpful to document thyroid status given the MTC black-box warning [2]
• Urinary albumin-to-creatinine ratio (UACR): recommended annually in type 2 diabetes per ADA 2024 [9]

Labs drawn at a local clinic (LabCorp, Quest, or a Montana Critical Access Hospital outpatient lab) can be shared with a telehealth provider electronically before the visit.

Who Can Prescribe Trulicity in Montana

Montana grants prescriptive authority to physicians (MD and DO), nurse practitioners, physician assistants, and clinical pharmacists with a collaborative practice agreement. No prescriber type is legally prohibited from initiating dulaglutide, provided they are practicing within their scope and are licensed by the appropriate Montana board [5].

The Montana Board of Medical Examiners and the Montana State Board of Nursing both maintain public license verification tools. Patients using telehealth should confirm that their provider holds an active Montana license before the visit, because out-of-state providers must be separately licensed in Montana to prescribe to Montana residents (or hold a valid Interstate Medical Licensure Compact credential) [11].

Per the Federation of State Medical Boards, the prescribing standard for telehealth is the same as for in-person care: the provider must establish a valid patient-provider relationship, conduct an appropriate evaluation, and document clinical reasoning [12]. An audio-only visit is generally insufficient to initiate a new prescription under Montana telehealth law; a synchronous video visit is the accepted standard [6].

Prior Authorization for Trulicity in Montana

Most Montana commercial insurers and Medicare Part D plans require prior authorization (PA) before covering Trulicity. Montana Medicaid does not currently cover Trulicity for the type 2 diabetes indication, making PA moot for Medicaid-only patients, who must use alternative funding pathways.

Standard PA documentation requirements across Montana commercial plans typically include:

1. Confirmed type 2 diabetes diagnosis (ICD-10: E11.x)
2. HbA1c at or above 7.0% on current therapy (most plans require 7.5% or higher)
3. Trial and inadequate response to metformin for at least 90 days (most plans specify 3 months)
4. Documentation of contraindication or intolerance if metformin was not used
5. Prescriber attestation of cardiovascular risk factors if the MACE indication is the basis for the request
6. Current medication list and any prior GLP-1 use

The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm recommends GLP-1 receptor agonists as preferred add-on therapy for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, citing REWIND and other cardiovascular outcomes trials [13]. Referencing this guideline in the PA letter can strengthen the clinical justification.

PA approvals for Trulicity typically take 3 to 14 business days in Montana. Peer-to-peer review is available in most cases if the initial request is denied.

Montana Medicaid and Coverage Alternatives

Montana Medicaid (Healthy Montana Kids Plus and the standard Medicaid expansion plan) does not list Trulicity on its preferred drug list for the type 2 diabetes indication as of the 2025 formulary update. Patients on Medicaid have two main alternatives:

Lilly Insulin Value Program / Lilly Cares. Eli Lilly offers the Lilly Cares Foundation patient assistance program for commercially uninsured or underinsured patients. Eligible patients may receive Trulicity at no or low cost [14]. Income thresholds and documentation requirements apply; applications are submitted at LillyCares.com or through a provider's office.

Lilly's $35 savings card. Commercially insured patients (not Medicaid or Medicare Part D) may use Lilly's savings card to cap their out-of-pocket cost at $35 per month [14].

Medicare Part D. Coverage varies by plan. Trulicity appears on the formularies of many Part D plans but often at Tier 3 or Tier 4, with out-of-pocket costs ranging from $45 to over $200 per month before the deductible is met. The Medicare Extra Help (Low Income Subsidy) program can reduce this cost significantly for qualifying patients [15].

GoodRx and cash-pay pricing. Without insurance, a four-pen carton of Trulicity (one month's supply) lists at approximately $900 to $975 at Montana retail pharmacies. GoodRx and similar discount programs bring this to approximately $650 to $800, varying by pharmacy and ZIP code [16].

Pharmacy Access and Shipping in Montana

Montana has retail pharmacies in most cities and larger towns, including chains (CVS, Walmart Pharmacy, Albertsons, Costco) and independent pharmacies. All are licensed by the Montana Board of Pharmacy and can fill a branded Trulicity prescription if stock is available.

Because Trulicity has experienced intermittent national supply constraints, calling ahead to confirm inventory is advisable. The FDA's drug shortage database tracks current availability [17].

Mail-order pharmacies. Mail-order pharmacies registered with the Montana Board of Pharmacy can ship Trulicity to any Montana address. Trulicity must be shipped refrigerated (36 to 46°F / 2 to 8°C) and can be kept at room temperature below 86°F for up to 14 days after removal from refrigeration, per the FDA label [2]. Carriers like UPS and FedEx offer temperature-controlled shipping options. For rural Montana addresses, next-day or two-day shipping is standard with most mail-order pharmacies.

503A compounding pharmacies. Montana-licensed 503A compounding pharmacies may compound dulaglutide with a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed compounding pharmacies to prepare drugs not commercially available in the needed form, or when there is a documented shortage [18]. Compounded dulaglutide is not FDA-approved and may differ in potency and sterility standards from the branded product. Patients considering compounded dulaglutide should ask their prescriber about the regulatory status and quality controls at the specific 503A pharmacy.

Clinical Evidence Supporting Dulaglutide

The REWIND trial (N=9,901, median follow-up 5.4 years) published in The Lancet in 2019 is the definitive cardiovascular outcomes study for dulaglutide [1]. REWIND enrolled patients with type 2 diabetes who had either established cardiovascular disease or at least two cardiovascular risk factors. Dulaglutide 1.5 mg weekly reduced the primary composite endpoint of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes by 12% relative to placebo (hazard ratio 0.88 to 95% CI 0.79 to 0.99, P<0.026) [1]. This result supported the FDA's 2020 label expansion and is the clinical basis for prescribing Trulicity in patients without diabetes who carry significant CV risk.

For glycemic control, the AWARD program of trials demonstrated that dulaglutide 1.5 mg reduced HbA1c by 1.1 to 1.6 percentage points from baseline across different background therapies [19]. AWARD-11 specifically showed that 3.0 mg and 4.5 mg doses produced additional HbA1c reductions of 0.4 to 0.5 percentage points beyond what the 1.5 mg dose achieved, supporting the higher-dose titration options now included in the FDA label [20].

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, or indicators of high cardiovascular risk, established kidney disease, or heart failure, a GLP-1 receptor agonist or SGLT-2 inhibitor with proven cardiovascular benefit is recommended" [9]. Dulaglutide, as a cardiovascular outcomes-proven GLP-1 agonist, satisfies this recommendation.

The AWARD-7 trial (N=577) evaluated dulaglutide specifically in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (eGFR 15 to 59 mL/min/1.73 m²). At 52 weeks, dulaglutide 1.5 mg reduced HbA1c by 1.1 percentage points and slowed eGFR decline compared with insulin glargine (P<0.005), providing evidence for use in CKD patients who represent a large portion of Montana's diabetic population [21].

Transferring an Existing Trulicity Prescription to Montana

Patients relocating to Montana can transfer a non-controlled medication prescription from an out-of-state pharmacy to a Montana pharmacy. Most retail pharmacy chains allow prescription transfers between stores in different states for non-controlled drugs [22]. The receiving Montana pharmacist will contact the originating pharmacy, verify the prescription details, and fill the remaining authorized refills.

If refills are exhausted, the patient needs a new prescription from a Montana-licensed provider. Telehealth makes this straightforward: a Montana-licensed clinician can review the patient's records, confirm the diagnosis and current dose, and issue a new prescription electronically, often within 24 to 48 hours.

Prescription transfers do not carry insurance authorizations across state lines automatically. If you had prior authorization under an out-of-state commercial plan, the same plan's Montana-based pharmacy benefit manager may require a new PA submission, particularly if the plan uses a different preferred pharmacy network in Montana.

Dosing, Titration, and What to Expect

Trulicity is initiated at 0.75 mg subcutaneously once weekly. After at least 4 weeks, the dose may be increased to 1.5 mg, then to 3 mg, and finally to 4.5 mg, each with a minimum 4-week interval between titrations [2]. The auto-injector pen is pre-filled and single-use; no mixing or reconstitution is required. Patients inject into the abdomen, thigh, or upper arm.

Common side effects include nausea (occurring in approximately 12 to 21% of patients across dose levels), diarrhea, vomiting, and decreased appetite [2]. Most gastrointestinal side effects are transient and peak within the first 2 to 4 weeks. Starting at the lowest dose and titrating slowly reduces their severity.

The FDA label carries a boxed warning for thyroid C-cell tumors observed in rodent studies. This does not establish causation in humans, but Trulicity is contraindicated in patients with personal or family history of MTC or MEN 2 [2]. Pancreatitis has been reported; the drug should be discontinued if pancreatitis is confirmed [2].

Once a patient is stable on a maintenance dose, the ADA recommends HbA1c checks every 3 months until the target is met, then every 6 months [9]. Annual eGFR and UACR monitoring is also recommended [9].